Last reviewed · How we verify
Minisiston (SH D00342A)
Minisiston is a progestin-only oral contraceptive that prevents pregnancy primarily through cervical mucus thickening and endometrial suppression.
Minisiston is a progestin-only oral contraceptive that prevents pregnancy primarily through cervical mucus thickening and endometrial suppression. Used for Oral contraception for pregnancy prevention.
At a glance
| Generic name | Minisiston (SH D00342A) |
|---|---|
| Sponsor | Bayer |
| Drug class | Progestin-only oral contraceptive (POP) |
| Target | Progesterone receptor |
| Modality | Small molecule |
| Therapeutic area | Contraception |
| Phase | Phase 3 |
Mechanism of action
As a progestin-only pill (POP), Minisiston works by increasing cervical mucus viscosity to impede sperm penetration and by altering the endometrium to reduce implantation likelihood. Unlike combined oral contraceptives, it contains no estrogen and relies on progestin activity alone for contraceptive efficacy.
Approved indications
- Oral contraception for pregnancy prevention
Common side effects
- Irregular menstrual bleeding
- Amenorrhea
- Headache
- Breast tenderness
- Nausea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Minisiston (SH D00342A) CI brief — competitive landscape report
- Minisiston (SH D00342A) updates RSS · CI watch RSS
- Bayer portfolio CI